↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Lisata Therapeutics$LSTA · filed: saw revenue fall 83.0% in FY2025 to $0MRotting at the dockNext year $0.0M–$0.1M sealedCheck ▾Close ▴
What Lisata Therapeutics filed
Saw revenue fall 83.0% in FY2025 to $0 million, operating margin -10711% against a -3.8% median for pharmaceutical preparations, equity 83.7% of assets. Every figure links to the filing it came from on Lisata Therapeutics’s card. Rotting at the dock: four or more warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $0.0M and $0.1M, an 80% range sealed on 20 Sept 2026 · receipt #28cfba · graded in public by the revenue in Lisata Therapeutics’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
**$4.00** cash offer with opaque CVR shifts post-close risk entirely to selling shareholders holding unsecured claims against private acquirer.
$4.00
per share in cash
$85 million
based on current diluted share count
21 days
absent extension
50.1%
of outstanding shares
Kuva Labs commenced its tender offer for Lisata Therapeutics at $4.00 per share in cash, structured with a non-tradeable contingent value right attached to each share. The offer values Lisata's equity at approximately $85 million based on current diluted share count, marking Kuva's entry into oncology therapeutics through the acquisition of Lisata's LSTA1 platform and cetrelimab programs.
The CVR component defers unspecified future value to selling shareholders, payable only upon achievement of milestones Kuva has not publicly detailed. Lisata's board unanimously recommended acceptance. The tender closes in 21 days absent extension, with a minimum tender condition of 50.1% of outstanding shares. Lisata reported $18.2 million in cash at September 30, 2024, against a quarterly burn rate near $6 million, suggesting approximately three quarters of runway absent this transaction. The $4.00 offer represents a 47% premium to Lisata's $2.72 closing price on the last trading day before announcement speculation began in early April.
The structure reveals Kuva's risk allocation preference. Cash consideration is certain and immediate. The CVR is neither tradeable nor SEC-registered, meaning selling shareholders cannot exit the contingent position, cannot mark it to market, and hold an unsecured contractual claim against a private acquirer. Kuva Labs remains privately held with no disclosed financial statements. The milestones triggering CVR payments are undefined in public filings, and the payment cap—if any—is undisclosed. This transforms Lisata shareholders into unsecured creditors of a private entity for any value beyond $4.00, with no visibility into Kuva's capital structure, leverage, or ability to perform on future obligations. The oncology asset Kuva is acquiring, LSTA1, is a tumor penetration technology designed to improve delivery of co-administered therapies. Lisata's cetrelimab, a PD-1 inhibitor, has completed Phase 1b/2 trials in pancreatic cancer with combination regimens. Neither asset has reached pivotal trial stage. Kuva's existing portfolio and capitalization remain opaque, raising questions about development funding and milestone probability.
Allocators and operators should monitor the tender's success threshold. If fewer than 50.1% of shares tender by close, the offer fails and Lisata continues as a publicly traded entity with diminishing cash. If the tender succeeds, watch for any disclosure of CVR milestone terms in the definitive merger agreement filed with the SEC within 10 days of tender close. Lisata's largest shareholders—approximately 23% institutionally held per last 13F filings—will determine outcome. Funds holding Lisata shares should model the CVR as zero and decide whether $4.00 cash reflects adequate compensation for relinquishing a publicly traded position. The absence of a tradeable CVR market means no price discovery and no ability to hedge.
Kuva's decision to use a CVR instead of raising the cash offer or issuing tradeable securities indicates either capital constraints or low confidence in near-term value crystallization. Lisata's board accepted the structure, suggesting limited alternative bids and urgent need to monetize before cash depletion in Q1 2025.
Branded by POPS4 · proof in 60 seconds
For the principal
CVR is illiquid unsecured debt to private entity; model as zero, decide if $4.00 justifies exit before Q1 cash exhaustion.
For the operator
Tender closes 21 days;watch 50.1% threshold and definitive merger filing for milestone disclosure within 10 days post-close.
For the house
Huang Goodman holds no position; monitoring CVR term disclosure as template for future sub-$100M biotech takeout structures with deferred consideration.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
